DynemicinA showedextremely potent in vitro cytotoxicity against a variety of murine and human tumor cells. In the experimental animal tumor models implanted ip with P388, L1210
Dynemicin A is a new antibiotic isolated from the culture broth of Micromonospora chersina sp. nov. M956-1 (ATCC53710), which contains the l,5-diyn-3-ene and anthraquinone subunit in the molecule. The isolation, chemical characterization, structure and some biological activities of dynemicin A have been reported previously1~3). Dynemicin A and its triacetyl derivative have been found to possess broad antimicrobial activity, especially potent against Gram-positive bacteria. On the whole, the latter was 2 to 8 times more active than the former1}. This paper describes the details of the in vitro cytotoxicity against murine and humantumor cells, in vivo antitumor activity in experimental animal tumor models and inhibition of macromolecule biosynthesis of dynemicin A and its triacetyl derivative.
Materials and Methods

Drug Preparation
Dynemicin A, triacetyldynemicin A and esperamicin Ax were prepared at Bristol-Myers Squibb Research Institute according to the procedures described in detail elsewhere4'5). For the in vitro and in vivo tests, they were dissolved in DMSO followed by dilution with sterile 0.9% NaCl or water. Doxorubicin (Kyowa Hakko), mitomycin C (Kyowa Hakko) and vincristine sulfate (Sigma) were used as a reference compound.
Animals
Female CDFi (Balb/c x DBA/2, 6-week old) and male BDFi (C57BL/6 x DBA/2, 5-week old) mice purchased from Japan SLCInc. (Hamamatsu) were used for in vivo antitumor evaluations. Feed and water were provided ad libitum through experiments.
Tumors
In vitro tumor cell lines, B16-F10 (murine melanoma), (Nissui) supplemented with 10% FCS, 2mML-glutamine and antibiotics (100/zg/ml streptomycin and lOO u/ml benzylpenicillin) was used as a growing medium.
Exponentially growing cells were harvested, counted and suspended in the culture medium at 1.5 x 104 (B16-F10), 2.5 x 104 (Moser), 3.0 x 104 (HCT-116), 1.3 x 104 (P388, P388/VCR and P388/ADM), 8.0 x 104 (K562 and K562/ADM) cells/ml, respectively.
After planting into wells of a 96-well or 24-well tissue culture plate with test materials, they were incubated for 72hours (B16-F10, Moser, HCT-116, P388, P388/VCR and P388/ADM) or 48 hours (K562 and K562/ADM). The cytotoxic activities against B16-F10, HCT-1 16 and Moser cells were colorimetrically determined at 540 nmafter staining viable cells with 0.008% neutral red solution while those against P388 and K562 cell lines were determined by directly counting the number of viable cells in a cell counter (Sysmex).
In Vivo Antitumor Activity
Murine leukemias P388 and L1210 were implanted ip with 106 and 105 cells per mouse or implanted iv with 5 x 105 and 104 cells per mouse, respectively. Murine melanomaB16 was implanted ip with 0.5ml of 10%tumor brei (on day 0). The graded doses of test materials were administered once a day on days 1 to 3 (Q1D x 3) ip or iv, or on days 1, 5 and 9 (Q4Dx 3) ip after tumor implantation. Death or survival of the drug-and vehicle-treated animals was recorded daily during the observation period of 45 days and median survival time (MST) was calculated for each of the test (T) and control (C) groups. A T/C value over 125%is considered significant antitumor effect.
Inhibition of Macromolecule Biosynthesis B16-F10 cells harvested and washed with the culture medium described above were planted into wells ofa 24-well tissue culture plate as 1.0ml aliquot of5 x 105 (for DNAand RNAsynthesis) or 1 x 105 (for protein synthesis) cells/ml. The plates were pre-incubated for 16 hours at 37°C in a 5%CO2 incubator. After that, the cells were exposed to test materials for 45 minutes at 37°C and then incubated with 7.4kBq [me%/-3H]thymidine, 7.4 kBq [2-14C] uridine or 29.6 kBq L-[4,5-3H]leucine for 30 minutes. After gently washing with cold 5%TCAsolution, the radio-activity incorporated into the acid-insoluble fraction was determined in a liquid scintillation counter (Aloka, LSC-701).
Acute Toxicity in Mice
Acute toxicity of dynemicin A was determined in male ddY mice weighing 20 to 24g after a single ip administration of graded doses of the antibiotic to groups of 5 to 8 mice. LD50value was calculated according to the method of Van der Waerden6) on day 10.
Results
In Vitro Cytotoxicity Both dynemicin A and its triacetyl derivative demonstrated extremely potent cytotoxicity against murine and humantumor cells, having IC50 values ranging from 0.0027 to 4.1 ng/ml, which indicate that they have similar or stronger cytotoxic potential than esperamicin At (Table 1) . Against human tumors such as Moser and K562 cells, their activities were 10,000~60,000 times superior to those of mitomycin C in terms of IC50 values. Dynemicin A was interestingly as active against drug-resistant sublines P388/VCR, P388/ADM and K562/ADM as against the corresponding sensitive cells. Tables 2 and 3 , dynemicin A administered ip gave significant chemotherapeutic activity against ip implanted P388 and L1210 leukemias. Although the maximumT/C values of dynemicin A were not high in both leukemias, the wide range of activity was seen and the antitumor activity was approximately 16-32 times more potent than that of mitomycin C in terms of minimumeffective dose. Similar anti-P388 leukemia activity was determined for the triacetyl derivative of dynemicin A. Both dynemicin A and its triacetyl derivative were also active against ip implanted B16 melanomawith maximumT/C values of 144-156% (Table 4) .
In Vivo Antitumor Activity As shown in
Whenadministered iv, dynemicin A demonstrated quite promising anti-leukemic activities against both iv implanted P388 and L1210 leukemias with maximumT/C values of 178 and 171%, respectively, the potency being approximately 8 -16 times stronger than that of doxorubicin (Table 5) .
Inhibition of Macromolecule Biosynthesis
Dynemicin A strongly inhibited the incorporation of [methyl-3H] thymidine into the acid-insoluble fraction of B16-F10 cells with IC50 value of 2.2ng/ml while the IC50 values for the incorporation of [2-14C] uridine and L-[4,5-3H]leucine were 8.5 and 14/ig/ml, respectively. These results indicate that the inhibitory effect of dynemicin A on DNAsynthesis was approximately 4,000 and 6,000 times stronger than that on RNAand protein synthesis, respectively.
Acute Toxicity in Mice When administered ip, dynemicin A demonstrated delayed-type toxicity in non-tumor-bearing mice. DEC. 1991 The first death of mice received lOmg/kg of dynemicin A, which was the highest dose tested, was seen at 3 days post-administration.
The LD50 value was determined to be 0.58mg/kg ip. Therefore, the acute toxicity of dynemicin A in mice was approximately 20 times less than that of esperamicin Ax (LD50 value: 0.026mg/kg ip).
Discussion
Dynemicin A is a novel antitumor antibiotic produced by M. chersina sp. nov. M956-1 (ATCC 53710) isolated from a soil sample collected in Gujarat State, India1*. According to the structural studies2'3*, dynemicin A is described to be an entry in the family of diynene antitumor antibiotics such as esperamicins5'7) and calicheamicin8). Since these antibiotics are receiving increasing attention due to their extremely potent antitumor activity9'10*, the in vitro and in vivo antitumor activities of dynemicin A were determined in comparison with its triacetyl derivative. Both dynemicin A and the triacetyl derivative achieved extremely potent in vitro cytotoxicity against murine and humantumor cell lines representing a variety of histological types. Dynemicin A administered ip also showed significant in vivo antitumor activity in mice against ip implanted P388 and L1210 leukemias and B16 melanoma with the wide range of activity. Similar antitumor results were obtained for the triacetyl derivative against both P388 leukemia and B16 melanoma. In the present experiments, one of the important characteristics for dynemicin A is antileukemic activity against iv implanted murine leukemias. Dynemicin A administered iv was 8~16 times more active against iv implanted P388 and L1210 leukemias than doxorubicin. Although dynemicin A gave more potent in vitro cytotoxicity than esperamicin Ax in all cell lines tested except in B16-F10, the acute toxicity in mice was approximately 20 times less than that of esperamicin Ax. Long et al.11 ] revealed in their alkaline elution studies that esperamicins in very low concentrations was capable of producing both single and double strand DNA breaks, and Zein et al.12) reported that calicheamicin interacted with double-helical DNA in the minor groove and caused site-specific double-stranded cleavage. Recently, Sugiura et al.13) described a possible mechanism of dynemicin A for DNAintercalation and cleavage. In the present experiments, dynemicin A specifically inhibited the incorporation of radio-labelled thymidine into the acid-insoluble fraction of B16-F10 cells. This result indicates that dynemicin A is a potent inhibitor of DNAsynthesis. The above evidence suggest that dynemicin A has specific and unique interaction with DNAmolecule and this may cause strong in vitro cytotoxicity and in vivo antitumor activity.
